FSD Pharma has named Zeeshan Saeed as its new chief executive officer (CEO).
FSD co-founder Saeed has been serving as its president since 2019.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
He was appointed by a unanimous vote held at its recent board of directors’ meeting.
Saeed will succeed the company’s co-founder, Anthony Durkacz, who had held the position of interim CEO since July 2021.
The two will continue as executive co-chairmen of the board of directors.
Under Saeed’s leadership, the company will streamline operations to focus on developing Unbuzzd, a product for the treatment of alcohol misuse. Unbuzzd supports the function of the liver and brain in rapidly alleviating the effects of alcohol intake. The company will target consumer and hospital markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFSD is also developing Lucid-MS for neurodegenerative ailments.
Durkacz stated: “I am incredibly honoured to have led FSD Pharma for the past two years, as we transitioned our business model and assembled a world-class team to develop and commercialise what I can only describe as potentially revolutionary products.
“As interim CEO, my task was to bring us to an inflection point and now that we are there, it is time to turn over to Zeeshan who I believe is the best fit to lead the team into [becoming] a revenue-producing company.”
